210 related articles for article (PubMed ID: 30746017)
1. Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Lodise T
Am Health Drug Benefits; 2018 Dec; 11(9):449-459. PubMed ID: 30746017
[TBL] [Abstract][Full Text] [Related]
2. Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models.
Lodise T; LaPensee K
Am Health Drug Benefits; 2019; 12(4):168-176. PubMed ID: 31428234
[TBL] [Abstract][Full Text] [Related]
3. Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Mistry R; Lodise T
Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 2):S13-S24. PubMed ID: 30996767
[TBL] [Abstract][Full Text] [Related]
4. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
5. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
[TBL] [Abstract][Full Text] [Related]
6. Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations.
Lodise TP; Fan W; Sulham KA
Clin Ther; 2016 Jan; 38(1):136-48. PubMed ID: 26708118
[TBL] [Abstract][Full Text] [Related]
7. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective.
LaPensee K; Mistry R; Lodise T
Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 1):S1-S12. PubMed ID: 30996766
[TBL] [Abstract][Full Text] [Related]
9. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
Jensen IS; Wu E; Fan W; Lodise TP; Nicolau DP; Dufour S; Cyr PL; Sulham KA
J Manag Care Spec Pharm; 2016 Jun; 22(6):752-64. PubMed ID: 27231802
[TBL] [Abstract][Full Text] [Related]
10. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
Lodise TP; Mistry R; Young K; LaPensee K
Clin Drug Investig; 2021 Mar; 41(3):269-275. PubMed ID: 33604769
[TBL] [Abstract][Full Text] [Related]
11. Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
Abrahamian FM; Sakoulas G; Tzanis E; Manley A; Steenbergen J; Das AF; Eckburg PB; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S23-S32. PubMed ID: 31367742
[TBL] [Abstract][Full Text] [Related]
12. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W; Green S; Overcash JS; Puljiz I; Metallidis S; Gardovskis J; Garrity-Ryan L; Das AF; Tzanis E; Eckburg PB; Manley A; Villano SA; Steenbergen JN; Loh E
N Engl J Med; 2019 Feb; 380(6):528-538. PubMed ID: 30726689
[TBL] [Abstract][Full Text] [Related]
13. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
Leviton IM; Amodio-Groton M
Clin Drug Investig; 2022 Mar; 42(3):193-197. PubMed ID: 35192150
[TBL] [Abstract][Full Text] [Related]
14. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Tanaka SK; Steenbergen J; Villano S
Bioorg Med Chem; 2016 Dec; 24(24):6409-6419. PubMed ID: 27469981
[TBL] [Abstract][Full Text] [Related]
15. Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a
Rodriguez GD; Warren N; Yashayev R; Chitra S; Amodio-Groton M; Wright K
Front Med (Lausanne); 2023; 10():1225710. PubMed ID: 37575994
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.
Lodise TP; Gunter K; Mu F; Gao E; Yang D; Yim E; Sandor S; Berman G
J Manag Care Spec Pharm; 2023 Aug; 29(8):952-964. PubMed ID: 37307087
[No Abstract] [Full Text] [Related]
17. Omadacycline: A New Tetracycline Antibiotic.
Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
[TBL] [Abstract][Full Text] [Related]
18. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
J Emerg Med; 2024 Mar; ():. PubMed ID: 38825531
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Huang X; Beresford E; Lodise T; Friedland HD
Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
